All Posts
For my dad
Those you love cannot be lost, because they are always a part of you. This blog is a Father's Day…
Phase 3 FIGHT-302 Results Presented at ASCO 2026 Evaluate Pemigatinib as a Potential First-Line Treatment Approach for Patients with FGFR2 Fusion- or Rearrangement-Positive Cholangiocarcinoma
Incyte's pemigatinib demonstrated a statistically significant improvement in progression-free survival compared with standard chemotherapy FOR IMMEDIATE RELEASEJune 12, 2026Karen TempletonSenior…
Community Champion: Sherry Yaeger Serves Others, Finds Purpose
Tell us a little about yourself. My name is Sherry, and I became involved with the Cholangiocarcinoma community with my…
ASCO 2026 Highlights: Precision Medicine Continues to Transform Cancer Care
Each year, thousands of cancer researchers, physicians, patient advocates, and industry leaders gather at the American Society of Clinical Oncology…
2026 Los Angeles Regional Symposium
The 2026 Los Angeles Cholangiocarcinoma Symposium is set to convene in Los Angeles, drawing together leading experts, researchers, healthcare professionals,…
2026 Houston Regional Symposium
The 2026 Houston Cholangiocarcinoma Symposium is set to convene in Houston, drawing together leading experts, researchers, healthcare professionals, patients, and…
Take Action: Provide Comments on Medical Care Barriers
The Centers for Medicare & Medicaid Services (CMS) is seeking public comments on how prior authorization policies affect patient access…
2026 Chicago Regional Symposium
The 2026 Chicago Cholangiocarcinoma Symposium is set to convene in Chicago, drawing together leading experts, researchers, healthcare professionals, patients, and…
2026 Annual Conference Poster Presentations
1 - Developing a Blood-Based Test for Diagnosis, Prognosis, and Monitoring of Cholangiocarcinoma 2 - Development of a Polygenic Risk…
Honoring Our Dedicated Fundraisers in Our 20th Year
As we say in our tagline, there is Strength in Community. The CCF community is built on compassion, resilience, and…